Comparing intestinal ultrasound with colonoscopy and enterography for people with ulcerative colitis and Crohn's disease
Prospective Evaluation of the Carbon Footprint and Clinical Utility of Intestinal Bowel Ultrasound Compared to Colonoscopy and Enterography in Ulcerative Colitis and Crohn's Disease
This project will see if intestinal ultrasound (IBUS) can provide the same clinical information as colonoscopy and enterography for people with ulcerative colitis or Crohn's disease while producing a smaller carbon footprint.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Asian Institute of Gastroenterology, India Academic / other |
| Locations | 2 sites (Hyderabad, Telangana and 1 other locations) |
| Trial ID | NCT07431983 on ClinicalTrials.gov |
What this trial studies
This prospective, observational project will enroll consecutive patients with ulcerative colitis or Crohn's disease who undergo endoscopy at AIG Hospitals. For each patient the study will record diagnostic findings from IBUS, colonoscopy, and enterography when available and will measure the real-world carbon footprint of each pathway including electricity, waste, sterilisation, and patient transportation. The trial will compare diagnostic concordance between IBUS and conventional imaging and quantify emissions differences using on-site data and standard carbon accounting methods. The goal is to determine whether IBUS can reliably inform clinical care with substantially lower environmental impact in routine practice at a tertiary gastroenterology center.
Who should consider this trial
Good fit: Ideal candidates are adults with established ulcerative colitis or Crohn's disease scheduled for endoscopy at AIG Hospitals who consent to additional ultrasound and environmental data collection.
Not a fit: Patients who require immediate therapeutic endoscopy, tissue biopsy for diagnostic purposes, or detailed cross-sectional imaging for complications such as abscesses or complex strictures may not benefit from IBUS alone.
Why it matters
Potential benefit: If successful, IBUS could offer a quicker, noninvasive monitoring option that reduces patient burden and the environmental impact of IBD care compared with colonoscopy and cross-sectional imaging.
How similar studies have performed: Prior clinical studies have increasingly supported IBUS accuracy for measuring IBD activity, but direct head-to-head comparisons that quantify environmental impact versus colonoscopy and enterography are limited.
Eligibility criteria
Show full inclusion / exclusion criteria
All consecutive patients undergoing endoscopy procedures with consent for procedures, during the study period will be included
Where this trial is running
Hyderabad, Telangana and 1 other locations
- AIG Hospitals — Hyderabad, Telangana, India (Recruiting)
- AIG Hospitals — Hyderabad, Telangana, India (Recruiting)
Study contacts
- Study coordinator: Dr.Hardik Rughwani
- Email: dr.hardikr@aighospitals.com
- Phone: 9426928600
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.